广州汇元医药科技

Guangzhou Huiyuan Pharmaceutical Technology is a clinical-stage biopharmaceutical company headquartered in Guangzhou, China, specializing in the development of innovative small molecule drugs. The company's research strategy focuses on metabolic diseases and oncology, aiming to address significant clinical gaps with First-in-class or Best-in-class potential. Its most advanced candidate, HY-0003, is a highly selective URAT1 inhibitor designed for the treatment of hyperuricemia and gout, currently undergoing Phase 2 clinical trials. The pipeline also includes HY-0002, a CDK4/6 inhibitor for oncology indications, and several other programs in early-stage development. Huiyuan Pharma integrates drug design, medicinal chemistry, and clinical operations to accelerate its therapeutic portfolio.